Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
Status:
Active, not recruiting
Trial end date:
2021-11-28
Target enrollment:
Participant gender:
Summary
JAVELIN Ovarian PARP 100 (B9991030) is an open-label, randomized study designed to evaluate
the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance
therapy of avelumab in combination with talazoparib versus an active comparator in
treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or
Stage IV). On March 19, 2019, Sponsors alliance announced the discontinuation of the ongoing
Phase III study, and the decision was based on several factors, including previous announced
interim results from JAVELIN Ovarian 100 study (B9991010). Patients who remain in B9991030
study will continue receiving their randomized treatment assigned and will be monitored for
appropriate safety assessments until treatment discontinuation.